Related Experiment Video
Updated: Feb 22, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
[Combination Therapy of Immune Checkpoint Inhibitors]
1Dept. of Experimental Therapeutics, National Cancer Center Hospital.
Abstract:
Recently, monotherapies of immune checkpoint inhibitor have been approved for some malignant tumors such as advanced melanoma, non-small cell lung cancer, renal cell cancer, Hodgkin lymphoma, head and neck cancer in Japan. As the next step, to aim improvement of the clinical benefit, development of combination immunotherapies including immune checkpoint inhibitors are ongoing. In this chapter, recent strategies of clinical development of combination immunotherapy are described.
Insights
Immune checkpoint inhibitors are approved for several cancers. Combination immunotherapies are now being developed to improve clinical benefits for patients with advanced cancers.
Area of Science:
- Oncology
- Immunotherapy
Background:
- Immune checkpoint inhibitor (ICI) monotherapies are approved for advanced cancers like melanoma and lung cancer in Japan.
- Further improvements in clinical outcomes are needed.
Purpose of the Study:
- To describe recent strategies in the clinical development of combination immunotherapies.
- To explore the potential of combining ICIs with other treatments.
Main Methods:
- Review of current clinical development strategies for combination immunotherapy.
- Analysis of ongoing research and trials involving immune checkpoint inhibitors.
Main Results:
- Combination immunotherapies involving ICIs are under active development.
- These combinations aim to enhance efficacy beyond monotherapy.
Conclusions:
- Combination immunotherapy represents the next frontier in cancer treatment.
- Ongoing development seeks to optimize treatment regimens for improved patient benefit.
More Related Videos
09:04Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
Related Concept Videos
Tumor Immunotherapy
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...